tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
CymaBay Therapeutics Inc (CBAY)
:CBAY
US Market
CBAY
CymaBay Therapeutics
Overview
Dividends
Statistics
New
Historical Prices
New
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

CymaBay Therapeutics (CBAY) Price & Analysis

Compare
― Followers

CBAY Stock Chart & Stats

Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

CymaBay Therapeutics News

CymaBay Therapeutics: Major Acquisition and Leadership Overhaul
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul
The latest announcement is out from CymaBay Therapeutics (CBAY). In a significant move for investors, a tender offer...
1y ago
8K
CBAY
Gilead completes acquisition of CymaBay
Gilead completes acquisition of CymaBay
Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for approximately...
1y ago
CBAY
GILD
Gilead says CymaBay deal to lower 2024 EPS by $3.35-$3.45
Gilead says CymaBay deal to lower 2024 EPS by $3.35-$3.45
Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for $4.3B...
1y ago
CBAY
GILD
CymaBay Therapeutics Revamps Executive Compensation Agreements
CymaBay Therapeutics Revamps Executive Compensation Agreements
The latest announcement is out from CymaBay Therapeutics (CBAY). CymaBay Therapeutics, Inc. has made significant changes to its...
1y ago
8K
CBAY
CymaBay announces European Medicine accepts for review the MAA for seladelpar
CymaBay announces European Medicine accepts for review the MAA for seladelpar
CymaBay Therapeutics announced that the Marketing Authorization Application, MAA, for seladelpar, for the treatment of primary biliary cholangitis,...
1y ago
CBAY
Savara price target raised to $16 from $7 at Piper Sandler
Savara price target raised to $16 from $7 at Piper Sandler
Piper Sandler raised the firm’s price target on Savara (SVRA) to $16 from $7 and keeps an Overweight...
1y ago
CBAY
SVRA
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
CymaBay Therapeutics Inc (CBAY) has disclosed a new risk, in the Corporate Activity and Growth category. CymaBay Therapeutics...
1y ago
CBAY
CymaBay reports Q4 EPS (35c), consensus (31c)
CymaBay reports Q4 EPS (35c), consensus (31c)
Reports Q4 revenue $57,000, consensus $40,000. “2023 was a seminal year for CymaBay with critical achievements in the...
1y ago
CBAY
CymaBay’s seladelpar shows efficacy in Phase 3 study featured in NEJM
CymaBay’s seladelpar shows efficacy in Phase 3 study featured in NEJM
CymaBay announced that The New England Journal of Medicine – NEJM – has published detailed results from the...
1y ago
CBAY
CymaBay downgraded to Market Perform from Outperform at Leerink
CymaBay downgraded to Market Perform from Outperform at Leerink
Leerink downgraded CymaBay Therapeutics to Market Perform from Outperform with a $32.50 price target after Gilead Sciences (GILD)...
1y ago
CBAY
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...
1y ago
ACST
ADIL
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...
1y ago
CBAY
GERN
CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital analyst Cory Jubinville downgraded CymaBay (CBAY) to Market Perform from Outperform with a $32.50 price target...
1y ago
CBAY
M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
M & A News: Gilead (NASDAQ:GILD) to Acquire CymaBay
Biopharmaceutical giant Gilead Sciences (NASDAQ:GILD) will acquire CymaBay Therapeutics (NASDAQ:CBAY) for $32.50 per share. This pegs the total...
1y ago
CBAY
GILD

CBAY FAQ

What was CymaBay Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is CymaBay Therapeutics Inc’s market cap?
Currently, no data Available
When is CymaBay Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CymaBay Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is CymaBay Therapeutics Inc overvalued?
According to Wall Street analysts CymaBay Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does CymaBay Therapeutics Inc pay dividends?
    CymaBay Therapeutics Inc does not currently pay dividends.
    What is CymaBay Therapeutics Inc’s EPS estimate?
    CymaBay Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does CymaBay Therapeutics Inc have?
    Currently, no data Available
    What happened to CymaBay Therapeutics Inc’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of CymaBay Therapeutics Inc?
    Currently, no hedge funds are holding shares in CBAY

    CymaBay Therapeutics (CBAY) Earnings & Revenues

    Currently, no data available
    Please return soon. This page is being updated.
    CBAY Earnings Data >

    Ownership Overview

    0.71%99.29%
    ―
    Insiders
    0.71%
    Mutual Funds
    ― Other Institutional Investors
    99.29% Public Companies and
    Individual Investors
    Detailed Ownership Overview >

    Options Prices

    Currently, No data available
    ---
    Popular Stocks

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing